Click Therapeutics
We're Hiring!
Click Therapeutics Company Growth, Stability & Outlook
What People Are Saying About Click Therapeutics
-
Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.
-
Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.
-
Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.
